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Key Points
• Survival after HCT vs
non-HCT therapeutic
options was compared
in patients with MF, with
results stratified by
DIPSS risk.
• A long-term survival
advantage of HCT was
observed in patients
with Int-1 or higher risk
MF, but at the cost of
potential early mortality.
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for
myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF
patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377
patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by
the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year
of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM),
HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS
intermediate 1 [Int-1]: hazard ratio [HR] 5 0.26, P , .0001; DIPSS-Int-2 and higher: HR, 0.39,
P , .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was
superior with non-HCT therapies compared with HCT in the first-year post treatment arm
assignment (HR, 0.16, P 5 .006). However, after 1 year, OS was not significantly different
(HR, 1.38, P5 .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT
therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1:
HR, 2.64, P, .0001; DIPSS-Int-2 and higher: HR, 2.55, P, .0001). In conclusion, long-term OS
advantage with HCTwas observed for patients with Int-1 or higher risk MF, but at the cost of
early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased
and became apparent with longer follow-up.
Introduction
Myelofibrosis (MF) is a myeloproliferative neoplasm character-
ized by clonal myeloid proliferation, extramedullary hematopoiesis,
peripheral cytopenias, bone marrow fibrosis, and heterogenous
symptom burden.1,2 With the discovery of the JAK2V617F driver
mutation in 2005 and subsequent innovation of JAK inhibitors, the
therapeutic landscape has evolved and led to significant improve-
ments in the clinical care of MF patients.3-6 Despite improvements
in patients’ symptom burden, splenomegaly, and potentially overall
survival (OS) with JAK inhibitor therapy, allogeneic hematopoietic
cell transplantation (HCT) remains the only curative therapy.7,8 The
morbidity and mortality associated with transplant therapy under-
scores the importance of appropriate patient selection for HCT.9-13
Currently, prognostic stratification is a key clinical feature of
transplant assessment in patients with MF. Multiple prognostic
scoring systems have assisted clinical decision-making over the
years, with more under development.14-20 The International Prognos-
tic Scoring System (IPSS) employs risk factors, including age .65
years, hemoglobin ,10 g/dL, white blood cell count .25 3 109/L,
circulating blasts $1%, and the presence of constitutional
symptoms.14 The IPSS highlighted that median survival varies
widely from 135 months in those with low risk disease to 27 months
in those with high-risk disease. While the IPSS is a useful prognostic
estimator at the time of diagnosis, the Dynamic IPSS (DIPSS) is
a similar prognostic estimator but may be used at any point during the
disease course.15 The DIPSS Plus has added risk factors such as
thrombocytopenia, transfusion dependence, and unfavorable karyo-
type.16 Contemporary prognostic models incorporate clinical, cyto-
genetic, and mutation data and advance MF prognostication.18,19,21
While emerging prognostic tools and clinical guidelines are useful
to facilitate appropriate patient selection for HCT, there is no
prospective and randomized data comparing HCT to non-HCT
therapies to guide clinical decision-making. This study reports on
survival outcomes of HCT vs non-HCT therapy, stratified by DIPSS
risk score, in the largest and most inclusive retrospective analysis
performed to date.
Methods
Study objective
The primary objective was an OS comparison between HCT and
non-HCT therapy in MF when stratified by DIPSS risk status.15
Secondarily, the patients’ disease and treatment-related factors
were evaluated for association with differences in survival.
Data source
For the HCT cohort, data were retrospectively obtained from the
Center for International Blood and Marrow Transplant Research
(CIBMTR) from years 2000 to 2014. The CIBMTR represents an
international network of .450 transplant centers that has collected
HCT outcomes data for.45 years, resulting in a research database on
.475000 patients. CIBMTR captures data including, but not limited
to, baseline recipient and donor characteristics, transplant outcomes,
and follow-up data at day 1100, day 1180, and annually after HCT.
For the non-HCT cohort, data were retrospectively obtained from
the Myeloproliferative Neoplasm Research Consortium and its
affiliates (a total of 14 academic centers; see supplemental Table 1)
between years 2000 and 2014 after approval from institutional
review boards of each participating study center. The Myeloprolif-
erative Neoplasm Research Consortium is an interactive group of
laboratory and clinical scientists from 11 institutions who work in
a coordinated fashion to develop and evaluate therapeutic
strategies that will improve the survival of patients with MF.
Study population
In the HCT cohort, patients with MF (either primary, postpolycythe-
mia, or post–essential thrombocythemia MF) who received an HCT
were included. Patients receiving HCT from an HLA-identical sibling
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or well-matched/partially matched unrelated donor after an ablative,
nonmyeloablative, or reduced intensity conditioning were included.
Patients who were aged $20 years and ,70 years at the time of
transplant were included. Patients who received umbilical cord
blood HCT, syngeneic HCT, or haploidentical HCT or patients who
have transformed to secondary acute myeloid leukemia prior to
HCT were excluded (n 5 63).
In the non-HCT cohort, patients with MF (either primary, post-
polycythemia, or post–essential thrombocythemia MF) who were
$20 years and ,70 years were included. Those in the non-HCT
cohort who were only observed and never on medical treatment
were excluded, because they are likely not the ideal comparator for
the HCT cohort.
Study variables
Patient-related variables, including age at diagnosis and HCT, race,
and Karnofsky performance status (KPS), were collected. Disease-
related variables, including diagnosis of primary vs secondary MF,
DIPSS at HCT or time of initial treatment/referral to academic
center, cytogenetics (favorable: normal karyotype; 13q2, 20q2;
unfavorable: complex aberrations or noncomplex abnormalities,
including 18, 27/7q2, i(17q), 25/5q2, 12p2, inv(3), or 11q23
rearrangements), and presence/absence of the JAK2V617F were
captured. Treatment was recorded, including type and number
of medical therapies, HLA matching, graft source, conditioning
regimen, total body irradiation delivery, and graft-versus-host
disease (GVHD) prophylaxis. Time from diagnosis to HCT or time
of initial treatment/referral to academic center, date of death, or
date of last contact was collected.
Statistical analysis
A descriptive analysis comparing the HCT and the non-HCT
cohorts was performed. Medians, ranges, and percentages of total
numbers were evaluated for categorical variables. The hazard ratio
(HR) for OS between the HCT and the non-HCT cohorts were
compared using the Cox proportional hazards model. The reference
time point was DIPSS assessment at time of initiation of medical
treatment or time of referral to academic medical center (if time of
initiation of medical treatment was unknown) for the non-HCT
cohort. The reference time point was DIPSS assessment at the time
of transplant for the HCT cohort. The proportional hazards
assumption of the Cox model was examined by testing a time-
varying effect for each variable. A time-dependent effect was
detected for the main effect, and a 12-month breakpoint of
posttherapy initiation/referral or transplant was found optimal based
on the maximized partial likelihood method to make sure the
proportional hazards assumption held within each time period.22
A stepwise model selection approach was then used to identify
all significant risk factors at a significance level .01. Potential
interactions between the main effect and significant risk factors was
tested. Adjusted OS probabilities were calculated to compare the
non-HCT cohort and the HCT cohort after adjusting for the
significant variables in the final Cox model.23 Adjusted OS was
obtained at 5 and 10 years. Multiple imputation with 10 imputations
was used to impute missing DIPSS risk scores and then confirmed
with the final Cox model using the assumption that missing data are
missing at random.24 The variables tested in the multivariable
regression analysis included age at DIPSS assessment, race, KPS,
primary vs secondary MF, ruxolitinib given as prior treatment,
time from diagnosis to DIPSS assessment, and year of DIPSS
assessment. Center effect was examined using the score test of
homogeneity through the frailty proportional hazards model with
random effects.25 The final Cox model was also fitted for each of the
DIPSS risk scores as a subset analysis. To investigate whether lead
time bias affected the main model given the fact that HCT patients
were guaranteed survival up to the point in which they underwent
transplant, a sensitivity analysis was performed restricting the time
between diagnosis and transplant to 12 months for the HCT cohort.
All analyses were performed at a significance level .01 using SAS
9.4 (SAS Institute, Cary, NC).
Results
Patient descriptive analysis
We identified a total of 551 MF patients who underwent HCT and
1377 MF patients treated with non-HCT therapy that met eligibility
criteria. See Table 1 for patient characteristics. Diagnosis included
primary MF in 463 patients (84%) in HCT group and 894 patients
(65%) in non-HCT group. Among the HCT cohort, 74.6% were
from the United States, while all the patients in the non-HCT cohort
were from US centers. The JAK2V617F mutation was detected
in 21% of HCT patients and 55% of non-HCT patients, and
JAK2V617F mutation data were unavailable in 64% and 14% of
patients, respectively. Other mutational analysis was not available.
DIPSS risk at time of transplant was low in 82 patients (15%),
intermediate 1 (Int-1) in 248 patients (45%), Int-2/high in 186
patients (34%), and missing in 35 patients (6%). In the non-HCT
patients, DIPSS risk was low in 165 patients (12%), Int-1 in 537
patients (39%), Int-2/high in 389 patients (28%), and missing in
286 patients (21%). Among the 1377 non-HCT patients, 88 (6%)
reported subsequently proceeding to HCT. The median time from
diagnosis to HCT was 19 months (range, 2-360) in the HCT group,
and the median time from diagnosis to referral was 2 months (,2383)
in the non-HCT group. The median follow-up time of survivors since the
reference time point was 72 months (range, 3-193) for HCT patients
and 63 months (,1-208) for non-HCT patients.
Transplant descriptive analysis
Donor types included well-matched unrelated (8/8 match) in 47%
of patients, HLA identical sibling/related in 38%, and partially
matched unrelated in 15%.26 Peripheral blood stem cell graft
source was used in 85% of patients, while bone marrow was used
in 15%. The transplant conditioning regimens were myeloablative
conditioning in 51% of patients, reduced intensity in 41%,
nonmyeloablative in 7%, and unknown in 2%.27 Total body
irradiation conditioning was employed in 20% of conditioning
regimens. Antithymocyte globulin was used in 36% of patients,
and alemtuzumab was used in 3%.
Survival analysis
The probability of survival for the 4 subgroups (DIPSS risk: low, Int-
1, Int-2, and high) with HCT vs non-HCT therapy is depicted in
Figure 1. In the DIPSS low-risk group, OS was superior with non-
HCT therapies compared with HCT in the first-year posttreatment
arm assignment, likely due to upfront transplant-related mortality
(TRM) risk. However, after 1 year, OS was not significantly different
(non-HCT: HR, 0.16; 95% confidence interval [CI], 0.04-0.59; P 5
.006 at ,12 months; and HR, 1.4; 95% CI, 0.60-3.20; P 5 .45
at . 12 months; Figure 1A). In the DIPSS Int-1 risk group, an OS
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advantage was present for HCT vs non-HCT therapies, but this OS
advantage was only observed beyond 1 year of treatment arm
assignment (due to high risk of TRM in the first year post-HCT) (non-
HCT vs HCT: HR, 2.64; 95% CI, 1.76-3.98; P , .0001 at ,12
months; non-HCT vs HCT: HR, 0.26; 95% CI, 0.17-0.39; P# .001
at.12 months; Figure 1B). Similarly, in those with DIPSS Int-2 and
high-risk MF, OS was superior in HCT cohort compared with non-
HCT therapies but only observed beyond 1 year of treatment arm
assignment (again due to high risk of TRM in the first year post HCT)
(non-HCT vs HCT: HR, 2.55; 95% CI, 1.66-3.90; P , .0001 at
,12 months; non-HCT vs HCT: HR, 0.39; 95% CI, 0.27-0.57; P,
.0001 at.12 months; Figure 1C). Across all risk groups, there was
a OS advantage observed with non-HCT therapies in the first year
of treatment arm assignment (due to high risk of TRM in the first year
post HCT) (non-HCT vs HCT: HR, 0.33; 95% CI, 0.26-0.41; P ,
.0001); however, OS was improved beyond 1 year of treatment arm
assignment with HCT (non-HCT vs HCT: HR, 2.11; 95% CI, 1.66-
2.69; P , .0001; Figure 1D).
By multivariable Cox regression, KPS ,90% (HR, 1.71; 95% CI,
1.49-1.98; P, .0001), DIPSS Int-1 or higher (Int-1: HR, 2.24; 95%
CI, 1.69-2.97; P , .0001; Int-2: HR, 3.33; 95% CI, 2.50-4.43; P ,
.0001; high: HR, 5.67; 95% CI, 3.81-8.44; P , .0001), and
unfavorable cytogenetics (HR, 1.45; 95% CI, 1.21-1.74; P ,
.0001) were associated with inferior survival in all patients. Prior
ruxolitinib therapy was associated with increased survival (HR, 0.53;
95% CI, 0.44-0.63; P, .0001) (Table 2). The adjusted survival rate
at 12 months after adjusting DIPSS, KPS, cytogenetics, and
ruxolitinib was 68% (64%-72%) for the HCT group and 87% (85%-
89%) for the non-HCT group based on a stratified Cox model.
The impact of HCT vs non-HCT on survival was consistent whether
patients received ruxolitinib or not (P value for interaction 5 .018).
Evaluation of the impact of year of referral/HCT on survival (ie,
before 2012 vs after 2012, the point at which ruxolitinib was
commercially available) revealed no significant association with
survival (P5 .38). Analysis after excluding partially matched donors
revealed no changes to the results (supplemental Table 3). Center
effect was not significant (P 5 .02).
To investigate whether lead time bias affected the main model given
the fact that HCT patients were guaranteed survival up to the point
in which they underwent transplant, a sensitivity analysis was
performed restricting the time between diagnosis and transplant to
12 months for the HCT cohort. This analysis revealed results
consistent with main survival results as reported in survival analysis,
suggesting minimal impact of lead time bias with chosen reference
time point (supplemental Table 4).
Adjusted OS was evaluated at 5 and 10 years (supplemental
Table 5). For the entire cohort not stratified by DIPSS, 10-year
adjusted OS was 47% (95% CI, 42% to 52%) and 35% (95% CI,
51% to 38%) for HCT and non-HCT (P # .0001), respectively.
Cause of death in HCT patients within the first year included GVHD
(23.8%), relapse of primary disease (21.1%), organ failure (15.7%),
infection (14.1%), acute respiratory distress (8.1%), graft failure
(3.8%), secondary malignancy (1.6%), and other causes (10.8).
Discussion
We studied survival outcomes in 1928 MF patients following HCT
(551 patients) or non-HCT (1377 patients) in the largest retrospec-
tive long-term survival analysis performed in MF to date. This study
Table 1. Descriptive characteristics for patients with MF
Variable HCT (n 5 551) Non-HCT (n 5 1377)
Primary MF, % 84 65
Secondary MF, % 16 35
Age at diagnosis, median (range), y 51 (20-69) 59 (20-75)
Median age at HCT/referral, y 55 61
DIPSS at HCT/referral, %
Low 15 12
Int-1 45 39
Int-2/high 34 28
Missing 6 21
Cytogenetics, %
Normal/favorable 52 73
Unfavorable 14 16
Missing 34 11
Origin, %
White 91 75
African American 4 6
Asian 3 2
Other 3 16
JAK2V617F mutation, %
Positive 21 55
Negative 15 32
Not tested or unavailable 64 14
Prior therapy, %
Ruxolitinib 10 30
Hydroxyurea 26 42
Immunomodulatory 14 26
Splenic irradiation 2 3
Number of prior therapies, %
0 28 16
1 36 25
2 17 24
$3 17 34
Conditioning intensity, %
MAC 51 —
RIC 41 —
NMA 7 —
Missing 2 —
Donor type
HLA identical 38 —
Well-matched unrelated 47 —
Partially matched unrelated 15 —
Median follow up time of survivors, mo 72 63
Time of diagnosis to treatment, mo 19 2
Number of centers 138 14
Unless otherwise indicated, the data are presented as percentage of patients.
MAC, myeloablative conditioning; NMA, nonmyeloablative; RIC, reduced intensity
conditioning.
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suggests a long-term survival advantage with HCT for patients
with Int-1 or higher risk MF, but with increased early mortality,
thus highlighting the need for careful patient selection and
continued development of therapies aimed at reducing post-
HCT complications.
Long-term survival post-HCT in MF is variable, ranging from 29% to
65% depending on patient and transplant variables, and data are
limited.10,12,13,28-45 Non-HCT therapies, including JAK inhibition,
are palliative only, and thus, HCT remains the only curative therapy.
In 2015, a consensus process guideline was developed by the
European Leukemia Net in conjunction with the European Blood
and Marrow Transplantation Group guiding allogeneic HCT
recommendations in MF.46 In these guidelines, patients with Int-2
or high-risk disease according to IPSS, DIPSS, or DIPSS Plus and
age,70 years should be considered potential candidates for HCT.
Patients with Int-1 disease and age,65 years were recommended
to be considered potential candidates if they present with either
transfusion-dependent anemia, percentage of blasts in the periph-
eral blood .2%, adverse cytogenetics as defined by the DIPSS
Plus classification, or high molecular risk (ie, JAK2/CALR/MPL
negative, ASXL1 positive).46
The data presented in this study indicate a long-term survival
advantage to HCT for patients with DIPSS Int-1 and higher risk MF,
independent of transfusion need, blast percentage, or high-risk
cytogenetic and molecular features. Clinicians may use the
survival curves from this analysis, illustrated in Figure 1, for
thorough HCT discussions and joint decision-making. These data
propose early consideration for HCT in selected MF patients
beginning with Int-1 risk identification and therefore may influence
clinical practice.
Although long-term survival was improved with HCT for Int-1 risk
and higher disease, this was at the cost of early TRM. The most
common causes of nonrelapse early (, 12 months) TRM were
GVHD (23.8%), organ failure (15.7%), and infection (14.1%).
Although great progress in management of HCT-related morbidity
has occurred in recent years, continued advancement of GVHD,
infectious, and supportive care therapy is still needed.47
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Figure 1. Survival probabilities for the DIPSS risk groups in MF receiving HCT vs non-HCT therapy. (A) DIPSS low risk. (B) DIPSS Int-1. (C) DIPSS Int-2 or higher.
(D) Overall (all DIPSS groups). The survival curves presented here, stratified by DIPSS risk score, are a representation of the interventions (ie, HCT vs non-HCT therapy) over
a median follow-up of ;6 years. The curves cross much later in the clinical course than 12 months; however, the slope of the curves changes much earlier (12 months) and
then plateaus, indicating the OS benefit associated with HCT begins much earlier than when the curves actually cross. A long-term survival advantage with HCT was observed
for patients with Int-1 or higher risk MF, but at the cost of early mortality. The magnitude of OS benefit increased as DIPSS risk score increased.
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The strength of our study is in the use of a Cox survival analysis that
allows for adjustment of covariates that likely govern the decision to
proceed to HCT (eg, age, KPS, and DIPSS score). We determined
that the ideal time to start the clock is at the time of DIPSS
assessment. This was at time of transplant for the HCT group and at
time of initiation of medical treatment or referral to academic medical
center (if time of initiation of medical treatment is unknown) for the non-
HCT arm.With this start time, the question the current study addresses
is which intervention (HCT or non-HCT) provides superior OS for
a patient with a particular DIPSS risk score that was able to live long
enough (and have sufficient resources, etc.) to present to the referral
center/HCT center. As such, the results presented here are most
clinically applicable to those presenting to a referral center or HCT
center and may not be applicable to other settings.
The impact of HCT on survival in patients ,65 years with primary
MF has previously been evaluated in 438 patients, revealing that the
HR of death after HCT vs those treated with non-transplant
modalities in low-risk DIPSS was 5.6 (P5 .0051); in Int-1 risk, it was
1.6 (P5 .19); for Int-2 risk, it was 0.55 (P5 .005); and for high-risk,
it was 0.37 (P5 .0007).10 In this analysis, the authors conclude that
patients with Int-2 or high-risk MF clearly benefit from HCT, while
those at low risk should receive nontransplant therapy. Individual
decision-making was recommended for Int-1–risk disease. In
contrast, the current analysis reveals survival benefit for those with
Int-1 disease and higher, supporting a stronger recommendation
for HCT in this population. While many similarities exist with
aforementioned study and the current analysis, the differences may
explain the discordant results with respect to the survival benefit
observed in the Int-1 patient population. The main differences are
that the current analysis includes a much larger sample size (1928
vs 438 patients), all types of MF (including secondary), older
patients (,70 vs ,65 years), and patients with prior exposure to
ruxolitinib (#30%).
Several factors should be considered when interpreting the results
of this analysis. The reference time point of HCT or referral to
academic center/start of medical therapy was estimated as the
most clinically relevant time point; however, it was recognized
a lead time bias was possible with this assumption. To investigate
whether lead time bias affected the main model (given the fact that
HCT patients were guaranteed survival up to the point in which
they underwent transplant), a sensitivity analysis was performed
restricting the time between diagnosis and transplant to 12months
for the HCT cohort revealing no significant change in the survival
analysis. Thus, lead time bias is estimated to have had little effect
on the survival analysis.
Another important consideration is the introduction of JAK inhibitor
therapy, which became commercially available in the United States
in 2012. We reviewed the impact of ruxolitinib with a multivariate
analysis, which revealed decreased risk of death with ruxolitinib
therapy (HR, 0.53; 95% CI, 0.44-0.63; P , .0001), consistent with
long-term follow up results of the COMFORT analyses.7 However,
the impact of HCT vs non HCT on survival was consistent whether
patients received ruxolitinib or not (P value for interaction 5 .018).
Another consideration in the HCT group is the donor source. In our
study, 15% of HCT patients received partially mismatched unrelated
donor transplants. We performed a sensitivity analysis after excluding
the partially matched donors. No major changes were noted in the
results, and thus, partially mismatched unrelated donor transplants
were included in the analysis (see supplemental Table 3). Cord blood
and haploidentical transplants were not included in this analysis due to
very low numbers and different outcomes.
Additional HCT factors must also be considered when interpreting
the results of the current analyses. Prior studies have suggested the
use of MAC rather than reduced intensity (RIC) were associated
with higher mortality rates however, optimal conditioning for MF
HCT is controversial.32,33,36,39,48,49 In this analysis, MAC was used
in 50% of transplant while RIC was used in 41% of patients
undergoing HCT. The impact of conditioning regimens was
examined and was not found to be significant (P5 .142). However,
the patient populations were different, and the impact of conditioning
on survival was not the purpose of this study.
The significant differences between the clinical-pathologic charac-
teristics between patients in HCT vs non-HCT cohorts must also be
considered. The median age of the transplant cohort was younger
(55 years) compared with the nontransplant cohort (61 years).
There were more white patients in the HCT cohort than the non-
HCT cohort; this difference may be partially explained by the
exclusion of cord and haploidentical transplant, as ethnic minorities
remain underrepresented in donor registries. There was a higher
proportion of secondary MF patients in the non-HCT group (35%)
vs those receiving transplant (16%); however, the impact of primary
vs secondary MF on survival is unknown.50 Unfavorable cytogenet-
ics in the non-HCT group were 16% vs 14% in the HCT group.
Therefore, it is recognized the groups are different and survival
analysis is potentially impacted. However, we controlled for these
observed imbalances in the Cox regression analysis.
Table 2. OS with multivariable regression analysis
HR 95% CI Overall P
OS (£12 mo) ,.0001
HCT 1
Non-HCT 0.325 0.260, 0.406
OS (>12 mo) ,.0001
HCT 1
Non-HCT 2.109 1.656, 2.685
DIPSS at HCT/referral ,.0001
Low 1
Int-1 2.237 1.683, 2.973
Int-2 3.327 2.496, 4.435
High 5.672 3.810, 8.443
KPS at HCT/referral ,.0001
$90% 1
,90% 1.713 1.485, 1.977
Cytogenetics .0004
Favorable (normal) 1
Favorable (other) 1.040 0.868, 1.245
Unfavorable 1.453 1.214, 1.740
Ruxolitinib ,.0001
No 1
Yes 0.530 0.444, 0.633
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Several limitations of the current study are recognized. The current
study and all retrospective analyses are burdened with the inherent
potential for bias and data-quality issues. A major limitation in this
study is lack of clear explanation of why patients were offered non-
HCT treatment modalities, including no data regarding the patient’s
comorbidities, raising concern of comparison between HCT and
non-HCT groups in the absence of this data. DIPSS score was
missing in 21% of non-HCT and 6% HCT; thus, more imputation was
necessary in the non-HCT arm. The current study is also limited in
molecular analysis, a major handicap in the modern era. It is now
recognized that the application of molecular and genetic data to
prognostic stratification models represents the future of personalized
therapy and transplant decision-making for MF.18,19,21 Additionally,
there was lack of comparative quality of life data, an important element
in transplant consideration. The impact of splenomegaly, splenectomy,
or splenic radiation was also not examined in this analysis. The effect of
splenomegaly on transplant outcomes is debated, with some studies
revealing a negative effect,37,51,52 others finding no effect,13 and others
with even a threefold increase in relapse rate after HCT.36 Additionally,
the applicability of DIPSS prognostic score, which was developed
originally in cohorts of patients with primary MF, is unknown in
secondary MF and requires further elucidation.50 New prognos-
tic schemas specifically in secondary MF patients are being
described.15,20 The retrospective nature of this study is another
limitation, but a randomized study comparing HCT to non-HCT
therapies is not likely to be performed in the United States. Thus,
this retrospective survival analysis is important for the practicing
clinician and may be useful to guide clinical practice.
In conclusion, this multicenter study evaluating survival of 1928 MF
patients with HCT vs non-HCT over a median of 6 years follow-up is
one of the largest andmost inclusive survival analyses performed in MF.
Our study suggests consideration of HCT in the setting of DIPSS Int-
1–risk MF, supports the accepted recommendation for HCT in DIPSS
Int-2/high-riskMF, and highlights the need for improved supportive care
strategies in MF in the early post-HCT period.
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